Giant cell glioblastoma
Citation, DOI & article data
Giant cell glioblastoma is a classic variant of glioblastoma (along with epithelioid glioblastoma and gliosarcoma) and although not distinct diagnoses, they continue to be recognized in the current (2021) WHO classification of CNS tumors 8. This tumor was previously called monstrocellular tumor due to the large size of its cells.
This neoplasm represents ~5% of GBM cases 1, with wider age range with a tendency to affect younger individuals than does conventional GBM 3, and accounts for about 1% of primary brain tumors.
The clinical features are similar to glioblastoma in general and patients could present a focal neurological deficit, symptoms of increased ICP, and seizures.
Giant cell glioblastomas are usually encountered in the cerebral hemispheres but can occur at any site in the central nervous system. There are some reports of extradural 6 and spinal leptomeningeal 5 metastases.
As is the case with some gliosarcomas, giant cell glioblastomas often have abundant connective tissue resulting in firm and circumscribed tumors reminiscent of cerebral metastases or even meningiomas 7. In other instances, connective tissue is minimal and appearances are indistinguishable from glioblastomas.
Giant cell glioblastoma is defined as a glioblastoma with a marked predominance of bizarre multinucleated giant cells that can be up to 0.5mm in diameter 1,7.
This tumor contains a high frequency of TP53 mutations (70-90%) and less commonly PTEN mutations (33%) and TERT mutations (25%) 2,7. EGFR amplification and IDH mutations are rare (i.e. they are IDH wild-type) 7.
Giant cell glioblastomas have no distinguishing features when compared to runofthemill glioblastoma 4.
Treatment and prognosis
Giant cell glioblastoma overall survival is superior when compared to patients with conventional IDH wild-type glioblastoma, although it remains poor with only ~10% 5-year survival and a median survival of 11 to 13 months 1,3,7.
History and etymology
This tumor was first described by Alexander Schmincke (1877-1953), a German pathologist 1.
On imaging the differential is primarily:
- conventional glioblastoma: usually indistinguishable
- cerebral metastases
- meningioma: if abutting the dura
Histologically, pleomorphic xanthoastrocytoma (PXA) is one important differential diagnosis, as both have in common the presence of giant tumor cells, infiltration of lymphocytes, deposition of reticulin and gross circumscription 4. Neuronal markers, positive in PXAs, are negative in giant cell glioblastomas.
- 1. Kozak K & Moody J. Giant Cell Glioblastoma: A Glioblastoma Subtype with Distinct Epidemiology and Superior Prognosis. Neuro Oncol. 2009;11(6):833-41. doi:10.1215/15228517-2008-123 - Pubmed
- 2. Peraud A, Watanabe K, Schwechheimer K et-al. Genetic profile of the giant cell glioblastoma. Lab. Invest. 1999;79 (2): 123-9. Pubmed citation
- 3. Margetts JC, Kalyan-Raman UP. Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure). Cancer. 1989;63 (3): 524-31. Pubmed citation
- 4. Valle-Folgueral J, Mascarenhas L, Costa J et al. Giant Cell Glioblastoma: Review of the Literature and Illustrated Case. Neurocirugia (Astur). 2008;19(4):343-9. doi:10.1016/s1130-1473(08)70221-5 - Pubmed
- 5. Chang C, Kuwana N, Ito S, Koike Y, Kitamura H. Spinal Leptomeningeal Metastases of Giant Cell Glioblastoma Associated with Subarachnoid Haemorrhage: Case Report. J Clin Neurosci. 2001;8(1):56-9. doi:10.1054/jocn.2000.0745 - Pubmed
- 6. Shinmura F, Chen M, Itoh T, Ariwa R. [An Autopsy Case of Extraneural Metastases of Giant Cell Glioblastoma with Intracerebral Hemorrhage]. No Shinkei Geka. 1985;13(11):1245-50. - Pubmed
- 7. International Agency for Research on Cancer, Otmar D. Wiestler. WHO Classification of Tumours of the Central Nervous System. (2016) ISBN: 9789283244929 - Google Books
- 8. Louis D, Perry A, Wesseling P et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro-Oncology. 2021;23(8):1231-51. doi:10.1093/neuonc/noab106 - Pubmed